Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development	$ 65,613	$ 76,735	$ 205,823	$ 221,964
Research and development related success payments and contingent consideration	(82,615)	(6,062)	(55,816)	(79,428)
General and administrative	19,183	15,514	52,515	48,240
Total operating expenses	2,181	86,187	202,522	190,776
Loss from operations	(2,181)	(86,187)	(202,522)	(190,776)
Interest income, net	2,862	1,173	7,212	2,149
Other income (expense), net	303	(106)	172	(406)
Net income (loss)	$ 984	$ (85,120)	$ (195,138)	$ (189,033)
Net income (loss) per common share - basic	$ 0	$ (0.45)	$ (1.01)	$ (1.01)
Weighted-average number of common shares - basic	196,978	189,303	193,605	187,645
Net income (loss) per common share - diluted	$ 0	$ (0.45)	$ (1.01)	$ (1.01)
Weighted-average number of common shares - diluted	200,473	189,303	193,605	187,645